These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 17851433)
61. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents. Cheng J; Qin J; Guo S; Qiu H; Zhong Y Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565 [TBL] [Abstract][Full Text] [Related]
62. Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors. Han L; Wang L; Hou X; Fu H; Song W; Tang W; Fang H Bioorg Med Chem; 2014 Mar; 22(5):1529-38. PubMed ID: 24525003 [TBL] [Abstract][Full Text] [Related]
63. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629 [TBL] [Abstract][Full Text] [Related]
64. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991 [TBL] [Abstract][Full Text] [Related]
65. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity. Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271 [TBL] [Abstract][Full Text] [Related]
66. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents. Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349 [TBL] [Abstract][Full Text] [Related]
67. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors. Zhang S; Huang W; Li X; Yang Z; Feng B Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653 [TBL] [Abstract][Full Text] [Related]
68. Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships. Poli G; Di Fabio R; Ferrante L; Summa V; Botta M ChemMedChem; 2017 Dec; 12(23):1917-1926. PubMed ID: 29117473 [TBL] [Abstract][Full Text] [Related]
69. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839 [TBL] [Abstract][Full Text] [Related]
70. Japonicones A-D, bioactive dimeric sesquiterpenes from Inula japonica Thunb. Qin JJ; Jin HZ; Fu JJ; Hu XJ; Wang Y; Yan SK; Zhang WD Bioorg Med Chem Lett; 2009 Feb; 19(3):710-3. PubMed ID: 19117757 [TBL] [Abstract][Full Text] [Related]
71. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC. Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459 [TBL] [Abstract][Full Text] [Related]
72. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595 [TBL] [Abstract][Full Text] [Related]
73. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Chen PC; Patil V; Guerrant W; Green P; Oyelere AK Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827 [TBL] [Abstract][Full Text] [Related]
74. Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Nam NH; Huong TL; Dung do TM; Dung PT; Oanh DT; Quyen D; Thao le T; Park SH; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB Eur J Med Chem; 2013; 70():477-86. PubMed ID: 24185378 [TBL] [Abstract][Full Text] [Related]
75. Synthesis, structural characterization and biological evaluation of N-protected cyclopropylethylcarbamates as potential histone deacetylase inhibitor. Jung JC; Moon HI; Oh S Chem Biol Drug Des; 2008 Dec; 72(6):592-5. PubMed ID: 19090926 [TBL] [Abstract][Full Text] [Related]
76. Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors. Kim HM; Hong SH; Kim MS; Lee CW; Kang JS; Lee K; Park SK; Han JW; Lee HY; Choi Y; Kwon HJ; Han G Bioorg Med Chem Lett; 2007 Nov; 17(22):6234-8. PubMed ID: 17904843 [TBL] [Abstract][Full Text] [Related]
77. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. Huong TT; Dung DT; Huan NV; Cuong LV; Hai PT; Huong LT; Kim J; Kim YG; Han SB; Nam NH Bioorg Chem; 2017 Apr; 71():160-169. PubMed ID: 28196602 [TBL] [Abstract][Full Text] [Related]
78. Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors. Choi E; Lee C; Park JE; Seo JJ; Cho M; Kang JS; Kim HM; Park SK; Lee K; Han G Bioorg Med Chem Lett; 2011 Feb; 21(4):1218-21. PubMed ID: 21256006 [TBL] [Abstract][Full Text] [Related]
79. Design, synthesis, and biological evaluation of novel amide and hydrazide based thioether analogs targeting Histone deacteylase (HDAC) enzymes. Farag AB; Ewida HA; Ahmed MS Eur J Med Chem; 2018 Mar; 148():73-85. PubMed ID: 29454918 [TBL] [Abstract][Full Text] [Related]
80. Synthesis of sulfonamides and evaluation of their histone deacetylase (HDAC) activity. Oh S; Moon HI; Son IH; Jung JC; Avery MA Molecules; 2007 May; 12(5):1125-35. PubMed ID: 17873846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]